{"source_content":"昊海生科（688366）证券研究报告·公司研究·医疗器械1/3东吴证券研究所请务必阅读正文之后的免责声明部分[Table_Main]收购全球化医美科技企业，医美产品不断丰富及差异化买入（维持）盈利预测与估值2019A2020E2021E2022E营业收入（百万元）1,6041,2891,6952,196同比（%）2.9%-19.7%31.5%29.6%归母净利润（百万元）371230426559同比（%）-10.6%-38.0%85.3%31.2%每股收益（元/股）2.091.302.403.15P/E（倍）58.2393.8950.6838.64投资要点事件：公司于2021年2月22日公告，将以共计人民币2.05亿元总投资款获得欧华美科63.64%的股权，本次交易完成后，拟对公司及欧华美科的产品及销售渠道进行整合。医美产品进一步拓展至“消费端”领域，将增加医用与家用皮肤护理光电设备。欧华美科通过控股（48.98%股权）以色列射频设备上市公司EndyMed，拥有从医用到家用的射频美肤设备产品；通过控股（55%股权）中国自主研发生产激光芯片及设备公司镭科光电，拥有激光美肤设备产品。公司收购欧华美科后，医美业务将进一步拓宽，并实现从“医疗端”向“消费端”延伸。其中，1）EndyMed射频设备包括用于纤体、改善皮肤的医用设备EndyMedPro、EndyMedPURE和用于面部除皱的家用设备Newa等，目前已取得美国FDA、FDA-OTC、欧盟CE认证、NMPA等全球16个国家和地区的上市许可并进行销售，家用美容仪器中国每年销量近5万台。2）镭科光电激光美肤设备已获得欧盟CE医疗器械认证，并于37个境外国家地区上市销售，目前其激光美肤设备及激光治疗系统2款美容设备正在申请美国FDA的上市许可，预期将于2021年底获批上市。激光美肤设备和皮秒激光设备2款美容设备正在申请NMPA上市许可，预期将分别于2021年和2023年获批上市。注射填充剂类型继续丰富，新适应症与新交联技术产品有望获批。欧华美科参股的BioxisPharmaceuticals为一家法国生物材料公司，其Cytosial玻尿酸填充剂，采用薄层交联专利技术使得凝胶分布均匀，无明显颗粒感，主要用于面部轮廓的注射填充，2019年欧盟上市当年实现销售约15万支。目前，欧华美科为Bioxis的3款在研玻尿酸产品开展在中国的临床试验及申请上市的工作，预期将陆续于2021年底至2022年底期间获批上市，其中2款产品目前中国尚无同类适应症产品上市销售，欧华美科将拥有3款产品在中国地区的独家经销权。此外，Bioxis在研的MTI12长效填充剂采用几丁糖类提取的生物材料，有望成为首款长效、可降解组织填充用几丁糖产品。业务协同与整合，医美板块综合竞争力有望提升。2019年欧华美科营业收入约2.4亿元，净亏损1222亿元，2020年收入因海外疫情有所下滑。目前欧华美科境内收入占比约45%，预计未来其业绩有望随着海外疫情好转及产品在国内上市销售等而改善。公司与欧华美科在技术、产品、销售、经销渠道方面的协同和整合，将进一步提升整体竞争力。盈利预测与投资评级：暂不考虑本次收购影响，预计2020-2022年公司归母净利润分别为2.30/4.26/5.59亿元，对应当前市值的PE为94X/51X/39X。公司全面布局眼科赛道，医美产品线不断丰富及差异化。维持“买入”评级。风险提示：新产品市场推广或低于预期；研发进展或不及预期；海外疫情持续蔓延等。[Table_PicQuote]股价走势[Table_Base]市场数据收盘价(元)121.83一年最低/最高价69.25/204.88市净率(倍)4.04流通A股市值(百万元)4807.00基础数据每股净资产(元)30.19资产负债率(%)9.09总股本(百万股)177.21流通A股(百万股)39.46[Table_Report]相关研究1、《昊海生科（688366）：业绩逐季恢复，Q3眼科骨科实现双位数增长》2020-10-282、《昊海生科（688366）：Q2业绩环比大幅改善，疫情不改长期增长趋势》2020-08-283、《昊海生科（688366）：自主研发+产业整合，国内眼科耗材龙头》2020-08-04[Table_Author]2021年02月22日证券分析师朱国广执业证号：S0600520070004021-60199793zhugg@dwzq.com.cn-46%-23%0%23%46%69%91%114%2020-022020-062020-10昊海生科沪深3002/3东吴证券研究所请务必阅读正文之后的免责声明部分[Table_Yemei]公司点评报告F昊海生科三大财务预测表资产负债表（百万元）2019A2020E2021E2022E利润表（百万元）2019A2020E2021E2022E流动资产3,9454,0024,2614,691营业收入1,6041,2891,6952,196现金3,2233,5063,2353,783减:营业成本364348424549应收账款382234576473营业税金及附加971013存货240178331329营业费用544496585747其他流动资产10183119105管理费用267258254307非流动资产2,2062,2482,4562,627财务费用-64-101-98-101长期股权投资5555资产减值损失-1000固定资产534550642733加:投资净收益21000在建工程357285284291其他收益7000无形资产614712830908营业利润435280521681其他非流动资产696696695690加:营业外净收支-1000资产总计6,1526,2496,7167,317利润总额434280521681流动负债360341356368减:所得税费用58397092短期借款5555少数股东损益6122530应付账款37345259归属母公司净利润371230426559其他流动负债318302299304EBIT338179420576非流动负债139138139139EBITDA438262519695长期借款1111其他非流动负债138138138138重要财务与估值指标2019A2020E2021E2022E负债合计499479495507每股收益(元)2.091.302.403.15少数股东权益199210235265每股净资产(元)30.7831.3833.7836.93归属母公司股东权益5,4555,5605,9866,545发行在外股份(百万股)178177177177负债和股东权益6,1526,2496,7167,317ROIC(%)5.3%2.8%6.0%7.6%ROE(%)6.7%4.2%7.2%8.7%现金流量表（百万元）2019A2020E2021E2022E毛利率(%)77.3%73.0%75.0%75.0%经营活动现金流349452-64737销售净利率(%)23.1%17.8%25.1%25.4%投资活动现金流-1,136-124-307-290资产负债率(%)8.1%7.7%7.4%6.9%筹资活动现金流1,393-4499101收入增长率(%)2.9%-19.7%31.5%29.6%现金净增加额609284-271548净利润增长率(%)-10.6%-38.0%85.3%31.2%折旧和摊销1008299119P/E58.2393.8950.6838.64资本开支39941208171P/B3.523.463.212.94营运资本变动-34228-515130EV/EBITDA37.2561.2231.4522.74数据来源：贝格数据，东吴证券研究所3/3东吴证券研究所请务必阅读正文之后的免责声明部分免责及评级说明部分免责声明东吴证券股份有限公司经中国证券监督管理委员会批准，已具备证券投资咨询业务资格。本研究报告仅供东吴证券股份有限公司（以下简称“本公司”）的客户使用。本公司不会因接收人收到本报告而视其为客户。在任何情况下，本报告中的信息或所表述的意见并不构成对任何人的投资建议，本公司不对任何人因使用本报告中的内容所导致的损失负任何责任。在法律许可的情况下，东吴证券及其所属关联机构可能会持有报告中提到的公司所发行的证券并进行交易，还可能为这些公司提供投资银行服务或其他服务。市场有风险，投资需谨慎。本报告是基于本公司分析师认为可靠且已公开的信息，本公司力求但不保证这些信息的准确性和完整性，也不保证文中观点或陈述不会发生任何变更，在不同时期，本公司可发出与本报告所载资料、意见及推测不一致的报告。本报告的版权归本公司所有，未经书面许可，任何机构和个人不得以任何形式翻版、复制和发布。如引用、刊发、转载，需征得东吴证券研究所同意，并注明出处为东吴证券研究所，且不得对本报告进行有悖原意的引用、删节和修改。东吴证券投资评级标准：公司投资评级：买入：预期未来6个月个股涨跌幅相对大盘在15%以上；增持：预期未来6个月个股涨跌幅相对大盘介于5%与15%之间；中性：预期未来6个月个股涨跌幅相对大盘介于-5%与5%之间；减持：预期未来6个月个股涨跌幅相对大盘介于-15%与-5%之间；卖出：预期未来6个月个股涨跌幅相对大盘在-15%以下。行业投资评级：增持：预期未来6个月内，行业指数相对强于大盘5%以上；中性：预期未来6个月内，行业指数相对大盘-5%与5%；减持：预期未来6个月内，行业指数相对弱于大盘5%以上。东吴证券研究所苏州工业园区星阳街5号邮政编码：215021传真：（0512）62938527公司网址：http://www.dwzq.com.cn","data":[{"id":"1","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"2019年中国医疗外科诊疗市场占整个医疗美容服务市场的58.2%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市占率","indicator_value":["58.20%","-1","-1"],"indicator_element":{"时间":["2019年","-1","4"],"区域":["中国","4","6"],"业务":["外科诊疗","8","12"],"行业":["医疗美容","17","21"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"达到人民币836亿元，复合年增长率为21.1%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模","indicator_value":["836亿元","4","9"],"indicator_element":{"时间":["2019年","953","958"],"区域":["中国","466","468"],"业务":["医疗外科诊疗","-1","-1"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"达到人民币836亿元，复合年增长率为21.1%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模年复合增长率","indicator_value":["21.10%","-1","-1"],"indicator_element":{"时间":["2019年","953","958"],"区域":["中国","466","468"],"业务":["医疗外科诊疗","-1","-1"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"中国私立医疗美容服务市场极度分散，CR5市场份额仅占总市场的7.2%（2017）","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市占率","indicator_value":["7.20%","-1","-1"],"indicator_element":{"区域":["中国","-1","1"],"行业":["私立医疗美容服务","1","9"],"公司":["CR5","16","19"],"时间":["2017","34","38"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"近五年行业规模快速增长，5年CAGR超30%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模年复合增长率","indicator_value":["30%","18","21"],"indicator_element":{"时间":["5年","11","13"],"行业":["医美","71","73"],"区域":["中国","466","468"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"2018年市场规模达1448亿元","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模","indicator_value":["2018年","-1","4"],"indicator_element":{"时间":["2018年","-1","4"],"行业":["医美","71","73"],"区域":["中国","466","468"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"5年CAGR达31.79%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模年复合增长率","indicator_value":["31.79%","6","12"],"indicator_element":{"时间":["5年","-1","1"],"行业":["医美","71","73"],"区域":["中国","466","468"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"医美行业市场增长迅速，中国医疗美容服务市场总收益达到1436亿","content_offset":["-1","-1"],"indicators":[{"indicator_name":"收入","indicator_value":["1436亿","25","30"],"indicator_element":{"区域":["中国","10","12"],"行业":["医疗美容","12","16"],"时间":["2019年","953","958"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"而2015年为人民币388亿元","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模","indicator_value":["388亿元","9","14"],"indicator_element":{"区域":["中国","466","468"],"业务":["医疗外科诊疗","-1","-1"],"时间":["2015年","0","5"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"2015年至2019年的复合年增长率为21.1%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模年复合增长率","indicator_value":["21.10%","-1","-1"],"indicator_element":{"时间":["2015年至2019年","-1","10"],"区域":["中国","466","468"],"业务":["医疗外科诊疗","-1","-1"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"美容非外科诊疗市场从2015年的人民币249亿元增至2019年的人民币600亿元，复合年增长率为24.6%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模","indicator_value":["249亿元","18","23"],"indicator_element":{"时间":["2015年","9","14"],"区域":["中国","466","468"],"行业":["美容非外科诊疗","-1","6"]},"indicator_supplement":{"属性":""}},{"indicator_name":"市场规模","indicator_value":["600亿元","34","39"],"indicator_element":{"时间":["2019年","25","30"],"区域":["中国","466","468"],"行业":["美容非外科诊疗","-1","6"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"美容非外科诊疗市场从2015年的人民币249亿元增至2019年的人民币600亿元，复合年增长率为24.6%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模年复合增长率","indicator_value":["24.60%","-1","-1"],"indicator_element":{"区域":["中国","466","468"],"行业":["美容非外科诊疗","-1","6"],"时间":["2019年","25","30"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"占2019年总市场约41.8%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市占率","indicator_value":["41.80%","-1","-1"],"indicator_element":{"区域":["中国","466","468"],"业务":["美容非外科诊疗","-1","-1"],"时间":["2019年","0","5"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"截至2024年，中国美容非外科诊疗市场预计将达到人民币1,443亿元","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模","indicator_value":["1,443亿元","26","33"],"indicator_element":{"区域":["中国","7","9"],"业务":["美容非外科诊疗","9","16"],"时间":["2024年","1","6"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"15","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"占市场总额约45.3%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市占率","indicator_value":["45.30%","-1","-1"],"indicator_element":{"区域":["中国","466","468"],"业务":["美容非外科诊疗","-1","-1"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"16","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"2019年全国取得医疗美容机构许可资质的医疗机构，包括综合医院的医疗美容科室、专科医院、门诊部、诊所约1.3万家","content_offset":["-1","-1"],"indicators":[{"indicator_name":"客户规模","indicator_value":["1.3万家","50","55"],"indicator_element":{"时间":["2019年","-1","4"],"区域":["全国","4","6"],"行业":["医疗美容","8","12"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"其中医院类医美机构占比为29.1%，门诊部类医美机构占比为32.9%，诊所类医美机构占比为38%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"客户规模占比","indicator_value":["29.10%","-1","-1"],"indicator_element":{"渠道":["医院类医美机构","1","8"],"时间":["2019年","953","958"],"区域":["全国","-1","-1"],"行业":["医疗美容","-1","-1"]},"indicator_supplement":{"属性":""}},{"indicator_name":"客户规模占比","indicator_value":["32.90%","-1","-1"],"indicator_element":{"渠道":["门诊部类医美机构","17","25"],"时间":["2019年","953","958"],"区域":["全国","-1","-1"],"行业":["医疗美容","-1","-1"]},"indicator_supplement":{"属性":""}},{"indicator_name":"客户规模占比","indicator_value":["38%","44","47"],"indicator_element":{"渠道":["诊所类医美机构","34","41"],"时间":["2019年","953","958"],"区域":["全国","-1","-1"],"行业":["医疗美容","-1","-1"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"2019年我国医美用户达1367.2万人","content_offset":["-1","-1"],"indicators":[{"indicator_name":"客户规模","indicator_value":["1367.2万人","11","19"],"indicator_element":{"时间":["2019年","-1","4"],"区域":["我国","4","6"],"行业":["医美","6","8"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"中国新一线城市的医美市场用户规模占比达到了35%，超过了一线城市的32%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"客户规模占比","indicator_value":["35%","20","23"],"indicator_element":{"区域":["中国新一线城市","-1","6"],"行业":["医美","7","9"],"时间":["2019年","953","958"]},"indicator_supplement":{"属性":""}},{"indicator_name":"客户规模占比","indicator_value":["32%","32","35"],"indicator_element":{"区域":["一线城市","2","6"],"行业":["医美","7","9"],"时间":["2019年","953","958"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"在用户方面，医美用户中的男性比例为13%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"客户规模占比","indicator_value":["13%","16","19"],"indicator_element":{"行业":["医美","5","7"],"性别":["男性","11","13"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"作为千禧一代的00后占比达到了15%左右，尽管相比47%的90后消费人群而言，仍不是主力消费人群","content_offset":["-1","-1"],"indicators":[{"indicator_name":"客户规模占比","indicator_value":["15%左右","14","19"],"indicator_element":{"年龄分布":["00后","6","9"],"行业":["医美","71","73"]},"indicator_supplement":{"属性":""}},{"indicator_name":"客户规模占比","indicator_value":["47%","24","27"],"indicator_element":{"年龄分布":["90后","28","31"],"行业":["医美","71","73"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"2019年，我国医美正规机构市场规模约878亿元","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模","indicator_value":["878亿元","18","23"],"indicator_element":{"时间":["2019年","-1","4"],"区域":["我国","5","7"],"行业":["医美","7","9"],"渠道":["正规机构","9","13"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"根据弗若斯特沙利文报告，2019年，民营机构收益占市场总收益的83.1%左右，达人民币1,193亿元，而2015年为人民币496亿元","content_offset":["-1","-1"],"indicators":[{"indicator_name":"收入","indicator_value":["1,193亿元","42","49"],"indicator_element":{"时间":["2019年","11","16"],"行业":["医美","71","73"],"渠道":["民营机构","17","21"]},"indicator_supplement":{"属性":""}},{"indicator_name":"收入","indicator_value":["496亿元","60","65"],"indicator_element":{"时间":["2015年","51","56"],"行业":["医美","71","73"],"渠道":["民营机构","17","21"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"2015年至2019年的复合年增长率为24.5%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"收入年复合增长率","indicator_value":["24.50%","-1","-1"],"indicator_element":{"行业":["医美","71","73"],"渠道":["民营机构","-1","-1"],"时间":["2015年至2019年","-1","10"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"私营机构医疗美容服务市场收益到2024年预计将达到人民币2,815亿元","content_offset":["-1","-1"],"indicators":[{"indicator_name":"收入","indicator_value":["2,815亿元","27","34"],"indicator_element":{"行业":["私营机构医疗美容服务","-1","9"],"时间":["2024年","14","19"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"26","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"自2015年至2019年，公共机构的医疗美容服务市场规模从人民币142亿元增至人民币243亿元，复合年增长率为14.4%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模","indicator_value":["142亿元","31","36"],"indicator_element":{"时间":["2015年","0","5"],"行业":["公共机构的医疗美容服务","12","23"]},"indicator_supplement":{"属性":""}},{"indicator_name":"市场规模","indicator_value":["243亿元","41","46"],"indicator_element":{"时间":["2019年","6","11"],"行业":["公共机构的医疗美容服务","12","23"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"自2015年至2019年，公共机构的医疗美容服务市场规模从人民币142亿元增至人民币243亿元，复合年增长率为14.4%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市场规模年复合增长率","indicator_value":["14.40%","-1","-1"],"indicator_element":{"行业":["公共机构的医疗美容服务","12","23"],"时间":["2015年至2019年","0","11"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"截至2024年，预计公共医疗美容服务市场收益将达到人民币370亿元","content_offset":["-1","-1"],"indicators":[{"indicator_name":"收入","indicator_value":["370亿元","27","32"],"indicator_element":{"时间":["2024年","1","6"],"行业":["公共医疗美容服务","9","17"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"29","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"2019年具备医疗美容资质的合法机构数量约为13000家，超范围经营的违规医美机构约为2000家，非法经营的医美机构数量约为8万家","content_offset":["-1","-1"],"indicators":[{"indicator_name":"客户规模","indicator_value":["约为13000家","19","27"],"indicator_element":{"渠道":["具备医疗美容资质的合法机构","4","17"],"时间":["2019年","-1","4"],"行业":["医美","36","38"]},"indicator_supplement":{"属性":""}},{"indicator_name":"客户规模","indicator_value":["约为2000家","40","47"],"indicator_element":{"渠道":["超范围经营的违规医美机构","28","40"],"时间":["2019年","-1","4"],"行业":["医美","36","38"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"合法合规开展医美项目的机构仅占行业12%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"市占率","indicator_value":["12%","16","19"],"indicator_element":{"行业":["医美","5","7"],"渠道":["合法合规开展医美项目的机构","-1","12"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"昊海生科（688366）：收购重组医美科技企业，医美产品不断丰富及差异化.pdf","content":"分渠道看，百度竞价等传统线上广告成本占比区间为60%-90%，美容院等线下转介机构成本占比为30%-70%，新氧等互联网平台成本占比区间为10%-30%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"成本占比","indicator_value":["60%-90%","22","29"],"indicator_element":{"渠道":["传统线上广告","9","15"],"区域":["国内","1257","1259"],"行业":["医美","71","73"]},"indicator_supplement":{"属性":""}},{"indicator_name":"成本占比","indicator_value":["30%-70%","45","52"],"indicator_element":{"渠道":["美容院等线下转介机构","30","40"],"区域":["国内","1257","1259"],"行业":["医美","71","73"]},"indicator_supplement":{"属性":""}},{"indicator_name":"成本占比","indicator_value":["10%-30%","68","75"],"indicator_element":{"渠道":["新氧等互联网平台","53","61"],"区域":["国内","1257","1259"],"行业":["医美","71","73"]},"indicator_supplement":{"属性":""}}]}]}